A Phase 3 interventional study of rimegepant 75 mg ODT and Matching placebo in Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps, sponsored by Pfizer. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.
Among the 83 studies in Nasal Polyps with a site in United States, this one is the 14th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2022, is one of 25 in phase 3, and was the 58th registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Japan, Puerto Rico
Ages 18+
GlaxoSmithKline · Sites in United States, Australia
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Airiver Medical, Inc. · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 27 · Phase 4 10
First in 2005; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 60 across the 71 interventional studies, 35 across the 12 observational. Of the 54 that completed or were terminated, 41 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 83 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
8 of the studies in Nasal Polyps with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07681973The Cleveland ClinicCognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training | 2026-12-31 |
| NCT07286201Polyganics BVEvaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF) | 2027-03 |
| NCT07599826Cedars-Sinai Medical CenterActive vs. Passive VR During Office-based ENT Procedures | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 83 studies in Nasal Polyps with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of rimegepant 75 mg ODT
Drug: rimegepant 75 mg ODT
One dose of matching placebo
Drug: Matching placebo
One dose of rimegepant 75 mg ODT
One dose of matching placebo
Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose
Facial pain/pressure/fullness was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no facial pain/pressure/fullness" and 10 being "worst imaginable facial pain/pressure/fullness." Higher scores signified worse condition.
Time frame: Baseline, 2 hours post-dose
Change From Baseline in Total Nasal Symptom Score (TNSS) at 2 Hours Post-Dose
TNSS was calculated as the sum of 3 symptom scores: facial pain/pressure/fullness, score ranged from 0 (no facial pain/pressure/fullness) to 10 (worst imaginable facial pain/pressure/fullness); nasal obstruction (congestion), score ranged from 0 (no nasal obstruction (congestion) to 10 (worst imaginable nasal obstruction (congestion); and nasal discharge, score ranged from 0 (no nasal discharge) to 10 (worst nasal discharge). TNSS overall score ranged from 0 (no nasal symptom) to 30 (worst nasal symptom); higher scores signified worse condition.
Time frame: Baseline, 2 hours post-dose
Change From Baseline in Nasal Obstruction (Congestion) at 2 Hours Post-Dose
Nasal obstruction (congestion) severity was assessed using a NRS ranging in integers from 0 (no nasal obstruction \[congestion\]) to 10 (worst imaginable nasal obstruction \[congestion\]). Higher scores signified worse condition.
Time frame: Baseline, 2 hours post-dose
Change From Baseline in Nasal Discharge at 2 Hours Post-Dose
Nasal discharge severity was assessed using a NRS ranging in integers from 0 (no nasal discharge) to 10 (worst imaginable nasal discharge). Higher scores signified worse condition.
Time frame: Baseline, 2 hours post-dose
Percentage of Participants With Headache Pain Relief at 2 Hours Post-Dose
Headache pain relief was defined as a headache pain level of none or mild at 2 hours post-dose on a 4-point Likert scale (0 = None; 1 = Mild; 2 = Moderate; 3 = Severe).
Time frame: 2 hours post-dose
Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose
Post 2 hours after dosing with study medication and after the 2-hour assessments were completed on the e-diary, participants were permitted to use the following rescue medications (non-study medications) such as: acetaminophen or aspirin, ibuprofen, naproxen (or any other type of nonsteroidal anti-inflammatory drug \[NSAID\]), oral antihistamines (non- sedating), oral decongestants, topical nasal decongestants, topical nasal anticholinergics.
Time frame: Through 24 hours post-dose
A total of 261 participants were enrolled and randomized in the study. Amongst which 99 received rimegepant and 105 received placebo.
| Milestone | Rimegepant 75 mg | Placebo |
|---|---|---|
| Started | 131 | 130 |
| Treated | 99 | 105 |
| Completed | 98 | 104 |
| Not completed | 33 | 26 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Randomized but not treated | 32 | 25 |
Facial pain/pressure/fullness was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no facial pain/pressure/fullness" and 10 being "worst imaginable facial pain/pressure/fullness." Higher scores signified worse condition.
| Scores on a scale | Rimegepant 75 mg | Placebo |
|---|---|---|
| Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose | -2.70 (-3.16 to -2.25) | -2.61 (-3.06 to -2.17) |
TNSS was calculated as the sum of 3 symptom scores: facial pain/pressure/fullness, score ranged from 0 (no facial pain/pressure/fullness) to 10 (worst imaginable facial pain/pressure/fullness); nasal obstruction (congestion), score ranged from 0 (no nasal obstruction (congestion) to 10 (worst imaginable nasal obstruction (congestion); and nasal discharge, score ranged from 0 (no nasal discharge) to 10 (worst nasal discharge). TNSS overall score ranged from 0 (no nasal symptom) to 30 (worst nasal symptom); higher scores signified worse condition.
| Scores on a scale | Rimegepant 75 mg | Placebo |
|---|---|---|
| Change From Baseline in Total Nasal Symptom Score (TNSS) at 2 Hours Post-Dose | -7.04 (-8.16 to -5.91) | -6.74 (-7.85 to -5.64) |
Nasal obstruction (congestion) severity was assessed using a NRS ranging in integers from 0 (no nasal obstruction \[congestion\]) to 10 (worst imaginable nasal obstruction \[congestion\]). Higher scores signified worse condition.
| Scores on a scale | Rimegepant 75 mg | Placebo |
|---|---|---|
| Change From Baseline in Nasal Obstruction (Congestion) at 2 Hours Post-Dose | -2.48 (-2.91 to -2.05) | -2.25 (-2.67 to -1.82) |
Nasal discharge severity was assessed using a NRS ranging in integers from 0 (no nasal discharge) to 10 (worst imaginable nasal discharge). Higher scores signified worse condition.
| Scores on a scale | Rimegepant 75 mg | Placebo |
|---|---|---|
| Change From Baseline in Nasal Discharge at 2 Hours Post-Dose | -1.81 (-2.22 to -1.41) | -1.85 (-2.25 to -1.45) |
Headache pain relief was defined as a headache pain level of none or mild at 2 hours post-dose on a 4-point Likert scale (0 = None; 1 = Mild; 2 = Moderate; 3 = Severe).
| Percentage of Participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants With Headache Pain Relief at 2 Hours Post-Dose | 59.4 (47.8 to 71.0) | 55.6 (44.7 to 66.4) |
Post 2 hours after dosing with study medication and after the 2-hour assessments were completed on the e-diary, participants were permitted to use the following rescue medications (non-study medications) such as: acetaminophen or aspirin, ibuprofen, naproxen (or any other type of nonsteroidal anti-inflammatory drug \[NSAID\]), oral antihistamines (non- sedating), oral decongestants, topical nasal decongestants, topical nasal anticholinergics.
| Percentage of Participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose | 7.3 (2.1 to 12.5) | 10.0 (4.1 to 15.9) |
Collected over Within 7 (+2) days post single administration of study medication (single dose was to be administered on any day from randomization to 45 days post randomization). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rimegepant | 0/99 (0%) | 0/99 (0%) | 4/99 (4%) |
| Placebo | 0/105 (0%) | 0/105 (0%) | 5/105 (4.8%) |
| Event | Rimegepant | Placebo |
|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 1/99 | 0/105 |
| Blood creatine phosphokinase increasedInvestigations | 1/99 | 0/105 |
| Upper respiratory tract infectionInfections and infestations | 1/99 | 0/105 |
| Head injuryInjury, poisoning and procedural complications | 1/99 | 0/105 |
| Dry throatRespiratory, thoracic and mediastinal disorders | 1/99 | 0/105 |
| DiarrhoeaGastrointestinal disorders | 0/99 | 1/105 |
| NauseaGastrointestinal disorders | 0/99 | 1/105 |
| Electrocardiogram PR shortenedInvestigations | 0/99 | 1/105 |
| HypertransaminasaemiaHepatobiliary disorders | 0/99 | 1/105 |
| Back painMusculoskeletal and connective tissue disorders | 0/99 | 1/105 |
| Age, Continuous(Years) | Rimegepant 75 mg | Placebo | Total |
|---|---|---|---|
| Mean | 48.6 ± 15.27 | 49.9 ± 15.83 | 49.3 ± 15.53 |
| Sex: Female, Male(Participants) | Rimegepant 75 mg | Placebo | Total |
|---|---|---|---|
| Female | 77 | 68 | 145 |
| Male | 54 | 62 | 116 |
| Ethnicity (NIH/OMB)(Participants) | Rimegepant 75 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 36 | 63 |
| Not Hispanic or Latino | 102 | 93 | 195 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Rimegepant 75 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 19 | 17 | 36 |
| White | 106 | 105 | 211 |
| More than one race | 0 | 3 | 3 |
| Unknown or Not Reported | 2 | 3 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2022 to primary completion in Mar 2024, 24 months.
Results were first posted in Mar 2025, 1 year after primary completion.
Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 24 months is close to that.
Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant